--News Direct--
By Johnny Rice, Benzinga
Mainz Biomed NV (NASDAQ: MYNZ) announced a major new collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to jointly develop a next-generation colorectal cancer screening product. The partnership will combine Thermo Fisher's advanced technologies with Mainz Biomed's proprietary mRNA-based screening tests, which focus on early detection of colorectal cancer and precancerous lesions.
Mainz CEO Guido Baechler highlighted the collaboration's potential to accelerate the development of a home collection screening tool with effective cancer detection. The collaboration will utilize Mainz Biomed's laboratories in Mainz, Germany, to leverage both companies' capabilities in developing advanced cancer screening technologies.
Learn more here:
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.
Contact Details
Benzinga
+1 877-440-9464
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/mainz-biomed-inks-major-deal-to-develop-a-next-generation-cancer-test-351740583
